Search PubMed⌕ Search

Biomedical subjects

M A Kratzer

Publications and source records attributed to M A Kratzer.

24 records · Page 2Linked to original sources

Detection of abnormal platelet functions with an in vitro model of primary haemostasis.

A new technique, which simulates primary haemostasis in vitro was tested using blood from control persons and from patients with a defined abnormality of primary haemostasis. The device allows the reproducible measurement of in vitro bleeding time and volume in small samples of whole blood. Inhibition of platelet adhesion and aggregation can very sensitively be detected with the new technique, which allows its possible use in clinical or pharmacological applications.

Blood Platelet Disorders↗

Source and concentration of extracellular adenosine triphosphate during haemostasis in rats, rabbits and man.

A new technique was developed for the measurement of extracellular free ATP in very small samples of whole blood using the luciferin-luciferase enzyme system. The method had a very low background corresponding to approximately 10(-16) mol ATP. ATP was measured in blood as it emerged during haemostasis following precise puncture of rat and rabbit arteries and after standardized incisions of human skin by the Simplate device. The initial concentration of free ATP in blood emerging 2-4 s after vascular injury was about 2 X 10(-7) M in rats and rabbits and about 2 X 10(-6) M in humans. The free-ATP concentration increased to 2 X 10(-5) M 3-5 min after injury and these increases could be prevented by heparin (20 u./ml). The source of the initial free ATP was identified as damaged cells in the injured vessel wall. Sufficient ADP, both released as such with ATP and generated by enzymic dephosphorylation of ATP, would be present at the site of injury to initiate haemostatic aggregation of platelets.

Adenosine Triphosphate↗

Aggregation of platelets in damaged vessels.

The only certain physiological function of platelets is their aggregation in injured vessel walls as haemostatic plugs. The association of thrombocytopenia with petechial haemorrhages suggests that platelets are somehow required for the functional integrity of small vessels, but no mechanism has yet been established. The pathological aggregation of platelets as thrombi in atherosclerotic arteries is commonly, if not always, initiated by haemorrhage. In artificial vessels, platelets tend to aggregate on the walls wherever blood flow is non-laminar. The mural aggregation of platelets is not prevented by unphysiologically high wall-shear forces. The facts suggest, on the contrary, that the process depends in some way on abnormal haemodynamic conditions. This contribution is mainly concerned with questions about how haemodynamic conditions in and around vascular leaks affect arriving platelets that aggregate there, and about the chemical agents responsible for making the platelets reactive. The effects of these agents are known mainly from in vitro experiments in which aggregation can be quantitatively correlated with biochemical effects by simple and reproducible methods; the relevance to their reactions in haemostasis and thrombosis is uncertain. It is difficult to devise quantitative methods for analysing these processes in vivo because of the very low concentrations at which endogenous agents can activate platelets and haemostasis factors in the plasma; the rapidity with which platelets aggregate in a damaged blood vessel; and the complexity and inconstancy of the haemodynamic situation. All these factors must be accounted for in hypotheses of haemostasis. New experimental approaches towards analysing the haemostatic mechanism in vivo are described.

Adenosine Diphosphate↗

Prediction of the transfusion effect of platelet concentrates as measured by a model of primary hemostasis ex vivo.

A method to determine primary hemostasis ex vivo (Thrombostat) was modified to monitor the transfusion effect of platelet concentrates (PC) in 12 patients with thrombocytopenia following bone marrow transplantation. It was possible to measure platelet function in patients with a platelet count lower than 2 x 10(10)/l. In addition, the platelet aggregometer (Born) was adapted to determine cell function in PC anticoagulated with acid citrate dextrose of citrate phosphate dextrose. It was possible to make a prediction (r = 0.89) of the effect of a given PC on a patient's ex vivo primary hemostasis parameters. Platelet aggregation following addition of 20 muM ADP to PC, obtained from 12 single donors, resulted in an average maximal light transmission (light transmission/age of concentrate in days) of 61%/1 day and 37%/5 days, respectively. The same experiment gave only 39%/1 day and 13%/4 days for pooled platelets. To avoid possible immunization and bleeding complications, a reliable monitoring of platelet transfusion seems highly desirable.

Bone Marrow Transplantation↗